ReviewFuture medicinal chemistry2025
Pyrimidine hybrids with
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advances in Pyrimidine Molecular Hybrids, Green Synthetic Strategies, and Diverse Biological Applications.ACS omega · 2026Review
- Design, synthesis and antiproliferative, apoptotic, and immunomodulatory properties of new heteroaryl pyridine-linked 1,2,4-oxadiazoles as prospective dual EGFR/BRAFRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy has transformed cancer from a catastrophic disease to a treatable and sometimes curable disease, but multidrug resistance is a predominant obstacle to effective chemotherapy, creating an urgent demand to explore novel anticancer therapeutics. Pyrimidine is necessary to maintain cellular fundamental function and is critical in cancer cell proliferation as well as survival, and some pyrimidine-based agents have been developed as anticancer therapeutics. In particular, pyrimidine hybrids can act on distinct biological targets in cancer cells simultaneously and have potential advantages in increasing anticancer therapeutic efficacy and circumventing drug resistance, indicating that the rational design of pyrimidine hybrids may provide valuable therapeutic interventions for cancer therapy. This review outlines the current scenario of the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.